57. Small E , Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration -resistant prostate cancer. Genitourinary Cancer Symposium 2009; abstract 7.